Roche Holding


Quality is beyond debate, valuations are not

17/11/26 -"In the last couple of years, most of Roche’s peers – including Novartis, AstraZeneca, Novo Nordisk and Sanofi – have suffered important R&D setbacks, whereas the Swiss giant has avoided major ..."

Pages
69
Language
English
Published on
17/11/26
You may also be interested by these reports :
17/11/26
In the last couple of years, most of Roche’s peers – including Novartis, AstraZeneca, Novo Nordisk and Sanofi – have suffered important R&D setbacks, ...

17/11/26
The factors discussed in the justification for DCF valuation have also prompted an upgrade to our NAV valuation. As a result, the target price resets ...

12/11/26
The Q3 results exceeded consensus estimates, backed by the strong showing of Electronics (driven by demand from AI applications) and healthy support ...

11/11/26
The Q3 profitability materially surpassed expectations, backed by the strong momentum for migraine and depression/schizophrenia treatments. The ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO